IRVING, Texas, Feb. 06, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (NASDAQ:RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with serious or life-threatening diseases, announced today that its senior management team will be presenting at the following investor conferences in the first half of 2017:

Canaccord Genuity Rare Disease Conference

• New York – February 7, 2017

Leerink Partners Global Healthcare Conference

• New York – February 15-16, 2017

Cowen & Co. Health Care Conference

• Boston – March 6-8, 2017

Barclays Capital Global Healthcare Conference

• New York – March 14-16, 2017

Deutsche Bank Health Care Conference

• Boston – May 3-4, 2017

Jefferies Global Healthcare Conference

• New York – June 6-9, 2017

About Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in regulating cellular metabolism and inflammation. Our two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target important transcription factors, called Nrf2 and NF-κB, to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

Contact:
Reata Pharmaceuticals, Inc.
(972) 865-2219
info@reatapharma.com
http://news.reatapharma.com

Investor Relations:
The Trout Group
Lee M. Stern, CFA
(646) 378-2922
IR@reatapharma.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.